Welcome to LookChem.com Sign In|Join Free
  • or
4-(cyclopropylmethoxy)benzoyl chloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1284199-22-9

Post Buying Request

1284199-22-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1284199-22-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1284199-22-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,4,1,9 and 9 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1284199-22:
(9*1)+(8*2)+(7*8)+(6*4)+(5*1)+(4*9)+(3*9)+(2*2)+(1*2)=179
179 % 10 = 9
So 1284199-22-9 is a valid CAS Registry Number.

1284199-22-9Relevant academic research and scientific papers

Synthesis of a stable triformylmethane synthon and its scalable application to 7-acylamino-3-formylquinoline syntheses

Sawai, Yasuhiro,Mizuno, Masahiro,Ito, Tatsuya,Yamano, Mitsuhisa

, p. 2370 - 2377 (2014/04/03)

Novel 2-iminiomethylvinamidinium trihalides were isolated as stable crystals and found to be useful triformylmethane synthons with non-deliquescent nature in air. They were easier to manufacture, handle, and store than the known 2-iminiomethylvinamidinium

BICYCLIC COMPOUND

-

Paragraph 1325; 1326; 1327, (2014/09/03)

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

8-benzamidochromen-4-one-2-carboxylic acids: Potent and selective agonists for the orphan G protein-coupled receptor GPR35

Funke, Mario,Thimm, Dominik,Schiedel, Anke C.,Müller, Christa E.

supporting information, p. 5182 - 5197 (2013/07/25)

8-Amido-chromen-4-one-2-carboxylic acid derivatives were identified as novel agonists at the G protein-coupled orphan receptor GPR35. They were characterized by a β-arrestin recruitment assay and optimized to obtain agonists with nanomolar potency for the

Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3- aminomethylquinolines: Reducing human ether-a-go-go-related gene (hERG) associated liabilities

Kasai, Shizuo,Kamata, Makoto,Masada, Shinichi,Kunitomo, Jun,Kamaura, Masahiro,Okawa, Tomohiro,Takami, Kazuaki,Ogino, Hitomi,Nakano, Yoshihide,Ashina, Shuntarou,Watanabe, Kaoru,Kaisho, Tomoko,Imai, Yumi N.,Ryu, Sunghi,Nakayama, Masaharu,Nagisa, Yasutaka,Takekawa, Shiro,Kato, Koki,Murata, Toshiki,Suzuki, Nobuhiro,Ishihara, Yuji

experimental part, p. 4336 - 4351 (2012/07/01)

Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-{3-[(1R)-1-{[2-(acetylamino)ethyl]amino} ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.

HETEROCYCLIC COMPOUND

-

Page/Page column 38, (2010/12/30)

The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound re

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1284199-22-9